Population-based Estimate of the Prevalence of HER-2 Positive Breast Cancer Tumors for Early Stage Patients in the US

被引：166

作者：

Cronin, Kathleen A. ^{[1
]}

Harlan, Linda C. ^{[2
]}

Dodd, Kevin W.

Abrams, Jeffrey S. ^{[3
]}

Ballard-Barbash, Rachel ^{[2
]}

机构：

[1] NCI, Stat Res & Applicat Branch, Surveillance Res Program, Bethesda, MD 20892 USA

[2] NCI, Appl Res Program, Bethesda, MD 20892 USA

[3] NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA

来源：

CANCER INVESTIGATION | 2010年 / 28卷 / 09期

关键词：

Breast carcinoma; HER-2/neu; Population-based study; SEER program; ADJUVANT CHEMOTHERAPY; HORMONE-RECEPTORS; ASSOCIATION; SURVIVAL; AMPLIFICATION; TRASTUZUMAB; EXPRESSION; WOMEN; RACE;

D O I：

10.3109/07357907.2010.496759

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The goal of this study was to estimate prevalence of HER-2 positive tumors in a population-based sample of 1026 women diagnosed in 2005 with early stage breast cancer. We modeled the relationship between patient and tumor characteristics and HER-2. HER-2 positive estimates were 19% for women aged < 49 years and 15% aged >= 50 years. HER-2 varied by tumor grade and size in women aged < 49 years but was not significant in multivariate analysis. Tumor grade and race were associated with HER-2 for women aged >= 50 years after controlling for other variables. HER-2 varies by age and by race and tumor in older women.

引用

页码：963 / 968

页数：6

共 17 条

[1]

*AM CANC SOC, 2006, CANC FACTS FIG 2006

[2]

Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue respository of the Surveillance, Epidemiology, and End Results (SEER) program [J].

Anderson, W. F. ;

Luo, S. ;

Chatterjee, N. ;

Rosenberg, P. S. ;

Matsuno, R. K. ;

Goodman, M. T. ;

Hernandez, B. Y. ;

Reichman, M. ;

Dolled-Filhart, M. P. ;

O'Regan, R. M. ;

Garcia-Closas, M. ;

Perou, C. M. ;

Jatoi, I. ;

Cartun, R. W. ;

Sherman, M. E. .

BREAST CANCER RESEARCH AND TREATMENT, 2009, 113 (01) :189-196

[3]

BORG A, 1990, CANCER RES, V50, P4332

[4]

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study [J].

Carey, Lisa A. ;

Perou, Charles M. ;

Livasy, Chad A. ;

Dressler, Lynn G. ;

Cowan, David ;

Conway, Kathleen ;

Karaca, Gamze ;

Troester, Melissa A. ;

Tse, Chiu Kit ;

Edmiston, Sharon ;

Deming, Sandra L. ;

Geradts, Joseph ;

Cheang, Maggie C. U. ;

Nielsen, Torsten O. ;

Moorman, Patricia G. ;

Earp, H. Shelton ;

Millikan, Robert C. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (21) :2492-2502

[5]

PROGNOSTIC IMPORTANCE OF C-ERBB-2 EXPRESSION IN BREAST-CANCER [J].

GUSTERSON, BA ;

GELBER, RD ;

GOLDHIRSCH, A ;

PRICE, KN ;

SAVESODERBORGH, J ;

ANBAZHAGAN, R ;

STYLES, J ;

RUDENSTAM, CM ;

GOLOUH, R ;

REED, R ;

MARTINEZTELLO, F ;

TILTMAN, A ;

TORHORST, J ;

GRIGOLATO, P ;

BETTELHEIM, R ;

NEVILLE, AM ;

BURKI, K ;

CASTIGLIONE, M ;

COLLINS, J ;

LINDTNER, J ;

SENN, HJ .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (07) :1049-1056

[6]

Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer [J].

Huang, HJ ;

Neven, P ;

Drijkoningen, M ;

Paridaens, R ;

Wildiers, H ;

Van Limbergen, E ;

Berteloot, P ;

Amant, F ;

Vergote, I ;

Christiaens, MR .

ANNALS OF ONCOLOGY, 2005, 16 (11) :1755-1761

[7]

Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer [J].

Huang, HJ ;

Neven, P ;

Drijkoningen, M ;

Paridaens, R ;

Wildiers, H ;

Van Limbergen, E ;

Berteloot, P ;

Amant, F ;

Vergote, I ;

Christiaens, MR .

JOURNAL OF CLINICAL PATHOLOGY, 2005, 58 (06) :611-616

[8]

Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related [J].

Huang, HJ ;

Neven, P ;

Drijkoningen, M ;

Paridaens, R ;

Wildiers, H ;

Van Limbergen, E ;

Berteloot, P ;

Amant, F ;

Christiaens, MR ;

Vergote, I .

BREAST CANCER RESEARCH AND TREATMENT, 2005, 91 (01) :81-87

[9]

Quantitative association between, HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer [J].

Konecny, G ;

Pauletti, G ;

Pegram, M ;

Untch, M ;

Dandekar, S ;

Aguilar, Z ;

Wilson, C ;

Rong, HM ;

Bauerfeind, I ;

Felber, M ;

Wang, HJ ;

Beryt, M ;

Seshadri, R ;

Hepp, H ;

Slamon, DJ .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (02) :142-153

[10]

Real-world performance of HER2 testing - National surgical adjuvant breast and bowel project experience [J].

Paik, S ;

Bryant, J ;

Tan-Chiu, E ;

Romond, E ;

Hiller, W ;

Park, K ;

Brown, A ;

Yothers, G ;

Anderson, S ;

Smith, R ;

Wickerham, DL ;

Wolmark, N .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (11) :852-854

← 1 2 →